The PTEN antibody, with a clone of SP218, is a rabbit monoclonal antibody that is designed to help advance the objective for personalized healthcare. Patients can lose PTEN from the body when they any number of cancers. There are many benefits of the PTEN antibody, including improved sensitivity, specificity, accuracy, and more.
The SP218 is more sensitive for FFPE tissues and offers a clear signal in the stroma and carcinoma. Therefore, it can be a useful tool for Immunohistochemistry applications and can help assess PTEN expressions in your cancer research. Likewise, it can provide a clear background and has a decreased incubation time compared to other antibodies, giving it more sensitivity and can help bring more developments into the lab.
The SP218 offers a more accurate interpretation of the antibody without as much background as other commercial antibodies. Its specificity has been confirmed by a single band in the Western Blot analysis, and it has a 100 percent concordance rate for prostate and colon cancer PTEN loss.
This antibody is designed specifically for IHC use and FFPE samples, making it the latest generation rabbit monoclonal antibody, offering robust staining and extreme sensitivity. Likewise, it has little or no cross-reactivity, making it more accurate and easier to pinpoint problems and situations. It can also be used with FACs and Western Blot analyses, providing single-source solutions with more precise results.
Developed by a company of excellence, it is consistent with IHC performances, making it the best choice for reproducible, reliable assessments and comparison diagnostics. It is available in a ready-to-use 7.0 ml version, as well as 0.5, 0.1, and 1.0 ml concentrated formulations, as well.
The PTEN antibody is monoclonal and works well in the research of various cancers. Visit Spring Bioscience now for more information.Add to favorites